Morgan Stanley Lowers Humana (NYSE:HUM) Price Target to $277.00

Key Points

• Morgan Stanley has reduced its price target for Humana (NYSE:HUM) from $290.00 to $277.00, with an "equal weight" rating indicating a potential upside of 10.33% from the previous close.
• Other analysts have varied opinions, with Piper Sandler lowering their target to $272.00 and Mizuho increasing theirs to $316.00, while Humana maintains an average target of $281.62 according to MarketBeat data.
• Humana's stock has seen fluctuations, trading down to $251.07 during mid-day trading, and the company reported a revenue of $32.39 billion for the last quarter, surpassing analyst expectations.

Humana (NYSE:HUM - Get Free Report) had its target price dropped by equities researchers at Morgan Stanley from $290.00 to $277.00 in a report released on Thursday,Benzinga reports. The brokerage presently has an "equal weight" rating on the insurance provider's stock. Morgan Stanley's price target would suggest a potential upside of 10.33% from the stock's previous close.

Several other analysts also recently weighed in on the company. Piper Sandler cut their target price on Humana from $288.00 to $272.00 and set a "neutral" rating on the stock in a research note on Thursday. Mizuho lifted their target price on Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a research note on Wednesday, April 9th. Truist Financial cut their target price on Humana from $280.00 to $260.00 and set a "hold" rating on the stock in a research note on Wednesday, July 16th. Raymond James Financial raised Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective on the stock in a research note on Thursday, May 1st. Finally, Oppenheimer boosted their price objective on Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a research note on Thursday, May 1st. Sixteen analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $281.62.

Humana Stock Performance

Shares of HUM traded down $10.41 during mid-day trading on Thursday, hitting $251.07. The stock had a trading volume of 1,505,129 shares, compared to its average volume of 1,738,673. The company has a market cap of $30.30 billion, a PE ratio of 17.69, a PEG ratio of 1.59 and a beta of 0.44. The company's fifty day simple moving average is $234.17 and its two-hundred day simple moving average is $255.74. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.71. Humana has a fifty-two week low of $206.87 and a fifty-two week high of $382.72.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). Humana had a net margin of 1.42% and a return on equity of 14.47%. The company had revenue of $32.39 billion for the quarter, compared to analyst estimates of $31.85 billion. During the same quarter in the prior year, the firm earned $6.96 EPS. The company's revenue for the quarter was up 9.6% compared to the same quarter last year. On average, equities analysts expect that Humana will post 16.47 earnings per share for the current year.

Hedge Funds Weigh In On Humana

Large investors have recently made changes to their positions in the business. PKO Investment Management Joint Stock Co raised its holdings in Humana by 140.0% in the 2nd quarter. PKO Investment Management Joint Stock Co now owns 4,800 shares of the insurance provider's stock valued at $1,174,000 after acquiring an additional 2,800 shares in the last quarter. AlphaQuest LLC raised its holdings in Humana by 35.4% in the 2nd quarter. AlphaQuest LLC now owns 1,925 shares of the insurance provider's stock valued at $471,000 after acquiring an additional 503 shares in the last quarter. ARGA Investment Management LP acquired a new position in Humana in the 2nd quarter valued at approximately $13,200,000. R Squared Ltd bought a new stake in shares of Humana in the 2nd quarter valued at approximately $214,000. Finally, Paralel Advisors LLC grew its stake in shares of Humana by 39.4% in the 2nd quarter. Paralel Advisors LLC now owns 10,096 shares of the insurance provider's stock valued at $2,468,000 after purchasing an additional 2,856 shares during the period. Institutional investors and hedge funds own 92.38% of the company's stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.